Bifurcation Lesions Market Report 2025

This Bifurcation Lesions market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The bifurcation lesions market size has grown strongly in recent years. It will grow from $2.63 billion in 2024 to $2.86 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rise in prevalence of coronary artery diseases, rise in geriatric population, rise in healthcare expenditure, economic growth.

The bifurcation lesions market size is expected to see strong growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing demand for minimally invasive surgeries, expansion of healthcare infrastructure and facilities, increasing prevalence of cardiovascular diseases, government healthcare policies. Major trends in the forecast period include patient-centric approaches, bioresorbable stents, integration of ai and machine learning, cross-specialty collaboration.

The growth of the bifurcation lesions market is expected to be driven by the increasing geriatric population. Individuals aged 60 and above are more susceptible to heart-related issues such as heart attacks, strokes, coronary heart disease, and heart failure. Bifurcation lesions play a crucial role in treating blood clots and facilitating adequate blood flow to the heart in such cases. A report by the World Health Organization (WHO) projected that by 2030, one in six people globally would be 60 or older, and by 2050, the number of individuals aged 80 and above would increase by 426 million compared to the current population. The rise in the geriatric population is anticipated to be a significant driver for the bifurcation lesions market.

The rising healthcare expenditure is expected to drive the growth of the bifurcation lesions market in the future. Healthcare infrastructure encompasses all expenses related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. Increased healthcare spending enables healthcare facilities to invest in cutting-edge equipment and technologies, including advanced interventional cardiology devices for treating bifurcation lesions. For example, in November 2023, the Canadian Institute for Health Information, a non-profit organization based in Canada, projected that total health spending in Canada would increase by 2.8% in 2023, following a modest growth of only 1.5% in 2022. Consequently, the rising healthcare expenditure is propelling the growth of the bifurcation lesions market.

A key trend gaining popularity in the bifurcation lesions market is the advancement in devices used in imaging and procedures. Leading companies in the market are focusing on enhancing existing devices used in imaging and procedures. For example, Advanced Bifurcation Systems (ABS), a clinical-stage medical device firm, has developed a unique bifurcation stenting solution featuring modular self-aligning stent technology. This platform aims to standardize the treatment of all bifurcation lesions in coronary angioplasties, providing a single system that reduces the need for repeat procedures and enables effective bifurcation stenting treatment. The trend towards device advancement is contributing to the growth and innovation in the bifurcation lesions market.

Leading companies in the bifurcation lesions market are actively developing innovative products such as drug-eluting coronary stent systems to expand their customer base, increase sales, and drive revenue growth. A drug-eluting coronary stent system is a specialized medical device used in interventional cardiology for the treatment of coronary artery disease. In August 2023, Medtronic PLC, an Ireland-based medical device company, introduced the Onyx Frontier drug-eluting stent (DES) to address non-left main bifurcation lesions using the provisional stenting technique. This product incorporates several design enhancements, including a dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility. The improvements result in a 16% enhancement in deliverability compared to the prior-generation Resolute Onyx DES, maintaining the same level of radial strength. Onyx Frontier offers an extensive range of sizes, accommodating patient needs with diameters ranging from 2.0mm to 5.0mm, with specific sizing for the treatment of extra-large vessels, including those in the left main. The product inherits clinical data and indications from Resolute Onyx, including approval for treating bifurcation lesions, left main percutaneous coronary intervention (PCI), and a recommended one-month duration of dual antiplatelet therapy (DAPT) for high bleeding risk patients.

In June 2024, Boston Scientific Corporation, a medical technology company based in the US, acquired Silk Road Medical, Inc. for $1.18 billion. The acquisition aims to enhance Boston Scientific's product offerings and competitive position in the vascular market by leveraging innovative technologies to improve patient outcomes and expand into new markets. Silk Road Medical, Inc. is a medical device firm that focuses on developing innovative solutions for carotid artery procedures.

Major companies operating in the bifurcation lesions market include Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics Corporation, Medtronic plc, Cardinal Health Inc., Cardinal Health Company, Abbott Laboratories, Biosensors International Group Ltd., B. Braun Melsungen AG, Cook Medical LLC, Cordis Corporation, Endologix Inc., W. L. Gore & Associates Inc., InspireMD Inc., MicroPort Scientific Corporation, OrbusNeich Medical Company Limited, Biotronik SE & Co. KG, Cardionovum GmbH, Elixir Medical Corporation, Medinol Ltd., Meril Life Sciences Pvt. Ltd., Opto Circuits (India) Ltd., QualiMed Innovative Medizinprodukte GmbH, Sahajanand Medical Technologies Pvt. Ltd., Svelte Medical Systems Inc., Translumina GmbH, Vascular Concepts Limited, Vascular Solutions Inc., Veryan Medical Ltd., X-Cell Medical Inc., Zorion Medical Inc., Amaranth Medical Inc., Cardiomind Inc., Cardiva Medical Inc.

Bifurcation lesions in the context of coronary arteries refer to constrictions that occur adjacent to or involve the origin of a critical side branch that one aims to preserve. This situation arises when there is an accumulation of plaque deposits, causing the artery to become too narrow, thereby hindering adequate blood flow to the heart.

The main categorizations of bifurcation lesions are one-stent and two-stent approaches. In a one-stent bifurcation lesion procedure, the side branch is provisionally stented if intervention is deemed necessary based on clinical complaints, angiographic results, or other relevant factors. In this approach, the main branch is stented first. The bifurcation angle is determined by the internal angle between the main and side branches. These types of bifurcation lesions are encountered in both coronary and peripheral vascular contexts.

The bifurcation lesions market research report is one of a series of new reports that provides bifurcation lesions market statistics, including bifurcation lesions industry global market size, regional shares, competitors with a bifurcation lesions market share, detailed bifurcation lesions market segments, market trends and opportunities, and any further data you may need to thrive in the bifurcation lesions industry. This bifurcation lesions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the bifurcation lesions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bifurcation lesions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bifurcation lesions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bifurcation lesions market includes revenues earned by proximal main branch (MB), distal MB and side branch (SB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.